Avalo Therapeutics (AVTX) Stock Soars on Positive Trial Data

Key Trial Success and Stock Surge

Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw its shares increase by 35% in after-hours trading. The surge followed the announcement of positive topline results from its Phase 2 LOTUS trial for abdakibart, a treatment for moderate to severe hidradenitis suppurativa.

LOTUS Trial Data Overview

The clinical trial successfully achieved its primary endpoint, HiSCR75, at Week 16 for both studied doses. The 150 mg dose demonstrated a response rate of 42.2%, while the 300 mg dose showed a 42.9% response rate. These figures compare favorably to the placebo group's response rate of 25.6%. The company noted these are the highest rates observed in a trial of this scale. The drug was also well tolerated with a favorable safety profile, with headache and nausea being the most common adverse events reported.

Financial and Development Impact

Following these positive results, Avalo Therapeutics plans to advance abdakibart into a registrational Phase 3 program. To finance this next stage, the company has commenced an underwritten public offering of common stock and pre-funded warrants. The net proceeds will be used for the clinical development of abdakibart through its Phase 3 data release, as well as for working capital and general corporate purposes. The offering is managed by Leerink Partners, TD Cowen, and BofA Securities as joint bookrunning managers.

Summary and Next Steps

Avalo Therapeutics is poised to move forward with its promising drug candidate, abdakibart, into late-stage clinical trials. The company intends to present the full, detailed results from the LOTUS trial at an upcoming medical congress. The success of the concurrent public offering will be a key factor in funding these crucial next steps.

FAQ

Q: Why did Avalo Therapeutics stock increase significantly?
A: The stock rose over 35% after the company announced positive results from its Phase 2 LOTUS trial for the drug abdakibart, a treatment for hidradenitis suppurativa.

Q: What was the primary endpoint met in the LOTUS trial?
A: The trial met its primary endpoint of HiSCR75, with response rates of 42.2% and 42.9% for its two doses, significantly outperforming the placebo rate of 25.6%.

Q: What are Avalo's plans following the trial results?
A: The company plans to advance abdakibart into a Phase 3 registrational program and has initiated a public offering to secure funding for its continued development.

Source: Investing.com